Current researches of clinical individualized medication and their evaluation1

Abstract

CLC Number:

HE Xi-Mei, LIU Xue-Wu, LI Xun-Xia. Current researches of clinical individualized medication and their evaluation¹[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(2): 237-240.

[1] 李家泰. 我国临床药理20 年— 在第七届全国临床药理学术会议上的报告[J].中国临床药理学杂志, 2000;16:3-9
[2] 於毓文. 血药浓度监测与给药方案个体化[A].见:吴莱文, 主编.治疗药物监测[M].第1 版.北京:人民卫生出版社, 1989:8-19
[3] Evans WE, Relling MV.Pharmacogenomics:translating fumctional genomics into rational therapeutics[J].Science, 1999; 286:487-91
[4] 戴德哉, 曹文.血浆药物浓度监测的临床意义[A].见:戴德哉, 主编.临床药理学[M].第1 版.北京:中国医药科技出版社, 2002:12-38
[5] 孙毓庆, 李发美, 邸欣.高效液相色谱法[A].见:孙毓庆, 主编.现代色谱法及其在医药中的应用[M].第1版.北京:人民卫生出版社, 2000:140-70
[6] 娄小娥, 阚连娣, 章辉.药物基因组学与个体化用药[J].中国临床药理学杂志, 2001;17:395-8
[7] March R.Pharmacogenomics:the genomics of drug respone [J].Yeast, 2000;17:16-21
[8] Shi MM, Bleavins MR, Delaiglesia FA.Technologies for detecting genetic polymorphism in pharmacogenomics[J].Mol Diagn, 1999;4:343-51
[9] Krynetsti EY, EvansWE.Pharmacogenetics as a moleular basis for individualived drug therapy:the thiopurine S-methyltransferase paradigm[J].Pharm Res, 1999;16:342-9
[10] Liggett SB.Pharmacogenetic applications of the human genome project[J].Nature Med, 2001;7:281-3
[11] Jain KK.Application of biochip and microarray systems in pharmacogenomics[J].Pharmacogenomics, 2000;1:289-307
[12] CroninMT, Pho M, Dutta D.Utilization of new technologies in drug trials and discovery[J].Drug Metab Dipsos, 2001;29:586-90
[13] Kawanish Y, Tachikawa H, Suzuki T.Pharmacogenomics and schizophrenia[J].Eur J Pharmacol, 2000;410:227-41
[14] Marshall A, Hodgson J.DNA chips:an array of possibilities [J].Nat Biotechnol, 1998;16:27-31
[15] 陶霞, 刘林.药物基因组学与高血压病的药物选择[J].中国临床药理学与治疗学, 2002;7:263-8
[16] Ferrari P.Pharmacogenomics:a new approach to individual therapy of hypertension[J] ? Curr Opin Nephrol Hypertens, 1998;7:217-22

Current researches of clinical individualized medication and their evaluation¹

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[2]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[3]	WANG Lin, YU Jianguo, LI Xiao, LUAN Jiajie. Establish and implement a pre-prescription system for outpatient based on Six Sigma DMAIC model [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 780-787.
[4]	HU Kangyi, CAO Linzhong, WAN Chaochao, SHANG Zhengya, YANG Xiaorui, ZHANG Yongjie. Research progress of traditional Chinese medicine regulating mitochondrial function in the treatment of steroid-induced femoral head necrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 688-696.
[5]	CAO Fang, QIN Kairong, ZHENG Guoshuang, ZHAO Dewei. Exploring the intervention mechanism of Ginkgo biloba for steroid-induced necrosis of the femoral head based on network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 266-275.
[6]	MA Guangli, ZHANG Jing. Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 315-322.
[7]	HOU Xiaoyu, LENG Yufang, CAO Xuefen, LV Xingjiao, HAN Xiaoxia, Janvier NIBARUTA, LIU Yongqiang. Network analysis and experimental verification of Schisandrin B reduces intestinal ischemia reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 147-154.
[8]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[9]	CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092.
[10]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[11]	GAO Lili, WANG Yuzhu, WANG Yan, LI Jian, WANG Jun. General considerations for clinical pharmacology of antitumor antibody-conjugated drugs: Implications from FDA review cases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 75-85.
[12]	XU Tao, ZHU Suyan, QIU Xiangjun, XU Ping. Population pharmacokinetics of teicoplanin in patients with renal insufficiency [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 977-983.
[13]	LIU Yanzhi, WANG Yan, LIU Kaili, ZHOU Wenhua, ZHU Ping, WANG Yingli, DU Shouying. Inhibition and mechanism of Xihuang pill on mice bearing hepatoma H22 tumor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 754-761.
[14]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[15]	YAO Qian, CHEN Yun, SHANG Juan, XI Xiaoyun, CHEN Ying, GU Xiao, JU Wenzheng, ZOU Jiandong, LU Su, XU Meijuan. Investigation of potential pharmacodynamic substances and mechanism of Qingxin-zishen prescription decoction in treatment of menopause syndrome based on HPLC-Q-TOF-MS/MS and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 481-497.